Calciscon Overview

  • Year Founded
  • 2013

Year Founded

  • Status
  • Private

  • Employees
  • 8

Employees

  • Latest Deal Type
  • Series A

  • Latest Deal Amount
  • $2.68M

  • Investors
  • 4

Calciscon General Information

Description

Developer of calcification propensity diagnostics equipment intended to improve the cardiovascular risk management of kidney patients. The company's calcification propensity test measures crystal formation time, magnesium in serum, and fetuin-A in serum as well as offers a measurement service for testing calcification propensity in blood, urine, or other sample types, enabling patients to identify patients at elevated risk to develop pathologic calcification.

Contact Information

Website
www.calciscon.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Diagnostic Equipment
Primary Office
  • Aarbergstrasse 46
  • 2503 Biel/Bienne
  • Switzerland
+41 032 000 00 00

Calciscon Timeline

2020202120222023
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Calciscon Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
8. Later Stage VC (Series A) 14-Apr-2021 $2.68M 00.000 Completed Generating Revenue
7. Later Stage VC 23-Jul-2020 00000 00.000 00.00 Completed Generating Revenue
6. Accelerator/Incubator 01-Sep-2017 00.00 Completed Startup
5. Debt - General 01-Jan-2016 00.00 Completed Startup
4. Seed Round 23-Mar-2015 00.000 00.00 00.00 Completed Startup
3. Grant 18-Jun-2014 00000 00000 Completed Startup
2. Accelerator/Incubator 07-Apr-2014 $147K $147K Completed Startup
1. Grant 03-Dec-2013 $164K Completed Startup
To view Calciscon’s complete valuation and funding history, request access »

Calciscon Cap Table

Stock # of Shares
Authorized		 Par Value Dividend Rate (%) Original
Issue Price		 Liquidation Liquidation
Pref. Multiple		 Conversion Price % Owned
Ordinary 00,000 000.00 000.00 00 000.00 00.000
Series Seed 00,000 000.00 000.00 00 000.00 00.000
To view Calciscon’s complete cap table history, request access »

Calciscon Executive Team (3)

Name Title Board Seat Contact Info
Vincent Linder Ph.D Chief Executive Officer & Board Member
Andreas Pasch MD Co-Founder, Chief Medical Officer, President & Chairman
You’re viewing 2 of 3 executive team members. Get the full list »

Calciscon Board Members (7)

Name Representing Role Since
Andreas Pasch MD Calciscon Co-Founder, Chief Medical Officer, President & Chairman 000 0000
Branford Lu Self Board Member 000 0000
Karsten Uhlmann Calciscon Board Member 000 0000
Peter Steinmann Calciscon Board Member 000 0000
Seppo Makinen Self Board Member 000 0000
You’re viewing 5 of 7 board members. Get the full list »

Calciscon Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Calciscon Investors (4)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Yellowstone Holdings Venture Capital Minority 000 0000 000000 0
W. A. de Vigier Foundation Limited Partner 000 0000 000000 0
Venture Kick Accelerator/Incubator Minority 000 0000 000000 0
Robert and Ruth Heuberger Foundation Limited Partner 000 0000 000000 0
To view Calciscon’s complete investors history, request access »

Ready to get started?

Request a free trial